Cefdinir: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cefdinir}} | {{Cefdinir}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Overview== | ==Overview== | ||
Cefdinir is a semi-synthetic, [[broad-spectrum antibiotic]] in the third generation of the [[cephalosporin]] class, proven effective for common [[bacteria]]l [[infection]]s of the ear, sinus, throat, and skin. It was approved by the U.S. [[Food and Drug Administration]] (FDA) in December of 1997. | Cefdinir is a semi-synthetic, [[broad-spectrum antibiotic]] in the third generation of the [[cephalosporin]] class, proven effective for common [[bacteria]]l [[infection]]s of the ear, sinus, throat, and skin. It was approved by the U.S. [[Food and Drug Administration]] (FDA) in December of 1997. | ||
==Category== | ==Category== | ||
Cephalosporin, Third-Generation | Cephalosporin, Third-Generation | ||
==US Brand Names== | ==US Brand Names== | ||
OMNICEF<sup>®</sup> | OMNICEF<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Cefdinir description|Description]]''' | |||
''' [[Cefdinir description|Description]]''' | |||
'''| [[Cefdinir clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Cefdinir clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Cefdinir microbiology|Microbiology]]''' | '''| [[Cefdinir microbiology|Microbiology]]''' | ||
| Line 27: | Line 31: | ||
'''| [[Cefdinir labels and packages|Labels and Packages]]''' | '''| [[Cefdinir labels and packages|Labels and Packages]]''' | ||
== Mechanism of | ==Mechanism of Action== | ||
Cefdinir is bactericidal except against [[Listeria monocytogenes]] where it is bacteriostatic. It inhibits bacterial wall synthesis like other [[beta-lactam]] antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by [[beta-lactamase]] or cephalosporinase. Resistance generally arises due to mutations in [[penicillin binding proteins]], production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.<ref name=Mosby> {{ cite book |title=Mosby's Drug Consult 2006 | publisher= Mosby, Inc. | date= 2006 | edition= 16 ed}} </ref> Unlike [[imipenem]], it is stable to dehydropeptidase-1 and can therefore be given without [[cilastatin]]. | Cefdinir is bactericidal except against [[Listeria monocytogenes]] where it is bacteriostatic. It inhibits bacterial wall synthesis like other [[beta-lactam]] antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by [[beta-lactamase]] or cephalosporinase. Resistance generally arises due to mutations in [[penicillin binding proteins]], production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.<ref name=Mosby> {{ cite book |title=Mosby's Drug Consult 2006 | publisher= Mosby, Inc. | date= 2006 | edition= 16 ed}} </ref> Unlike [[imipenem]], it is stable to dehydropeptidase-1 and can therefore be given without [[cilastatin]]. | ||
Revision as of 00:49, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Cefdinir is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
Category
Cephalosporin, Third-Generation
US Brand Names
OMNICEF®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Cefdinir is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamase or cephalosporinase. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[1] Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.
References
- ↑ Mosby's Drug Consult 2006 (16 ed ed.). Mosby, Inc. 2006.